Drug Discovery

DRAVET SYNDROME DRUG DEVELOPMENT PIPELINE REVIEW 2018

DRAVET SYNDROME DRUG DEVELOPMENT PIPELINE REVIEW 2018

The 2018 Dravet Syndrome Pipeline and Opportunities Review provides a review and analysis of 14 drug candidates in development for the treatment of Dravet syndrome, including 9 products that have received orphan drug designations. It also includes an analysis of the competitive landscape and evaluates current and future opportunities of the Dravet syndrome market. 

Genes vs syndromes at the International Epilepsy Congress in Barcelona

Genes vs syndromes at the International Epilepsy Congress in Barcelona

Should we talk about syndromes based on the gene that causes them or should we talk about them (and treat them) based on the clinical characteristics that they display?  Earlier this month, the epilepsy community gathered in Barcelona for the 32nd International Epilepsy Congress and there was a debate between genetic and symptom-base syndrome classification. This debate goes beyond semantics, and has important regulatory and access implications.

Dravet Syndrome Drug Development Pipeline Review 2017

Dravet Syndrome Drug Development Pipeline Review 2017

June 23 is a special day for families of people with Dravet syndrome. It is the International Dravet Syndrome Awareness Day, that in 2017 celebrates its 4th edition. That's why today we announce the publication of the 2017 Dravet Syndrome Pipeline and Opportunities Review, a market research publication that provides an overview of the global therapeutic landscape of Dravet syndrome.

2016 numbers: CNS orphan drugs growing

2016 numbers: CNS orphan drugs growing

With 2016 numbers now available, the number of orphan drugs in development for neurological indications is looking quite positive. I have reviewed the numbers of orphan drug designations and approvals by FDA in 2016 to see how popular are neurological orphan drugs today and what the trend is for the near future.

What marihuana teaches us about drug discovery

What marihuana teaches us about drug discovery

There was one clear star at the American Epilepsy Society Annual meeting this year, Epidiolex (cannabidiol). Yet four years ago no one would have thought that the cannabis-derived drug would take over the field of epilepsy in such a big way.

How close are we to creating transgenic people?

How close are we to creating transgenic people?

The journal Nature just released one of the most anticipated breaking news of the last few years: CRISPR gene editing has been tested in a person for the first time.  In my day-to-day work I interact with families that have a child with a genetic disease. I get one question a lot: how close are we to turn that discovery into a therapy for people with genetic diseases?